课题基金 / 基金详情

Characterization of Platelet-Derived Growth Factor-Induced p38 Mitogen-Activated Protein Kinase Activation and its Biological Effects in the Diabetic Vascular Wall Cells

Characterization of Platelet-Derived Growth Factor-Induced p38 Mitogen-Activated Protein Kinase Activation and its Biological Effects in the Diabetic Vascular Wall Cells
血小板衍生生长因子诱导的 p38 丝裂原激活蛋白激酶激活的表征及其在糖尿病血管壁细胞中的生物学效应
批准号:
12671097
负责人:
IGARASHI Masahiko
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2002

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The aim of this experiment was to examine the characterization of platelet-derived growth factor (PDGF)-induced p38 mitogen-activated protein kinase (p38) activation and its biological effects in the diabetic vascular smooth muscle cells (VSMCs). PDGF-BB activated p38 phosphorylation dose-dependently, and the level was more drastic in diabetic cells. These phosphorylations were specifically inhibited by SB-203580, a specific inhibitor of p38, but not by PD-98059. However, PDGF-BB did not affect the protein level of p38. PDGF-BB also activated the translocation of protein kinase C (PKC) - δ and the phosphorylation of MKK 3 / MKK 6 but not that of either stress-activated protein kinase. In the upstream level, PDGF-induced p38 activation was regulated the Rho A, one of the members of small G proteins. The amounts of DNA synthesis and migration stimulated by PDGF-BB were prevented by SB-203580 dose-dependently. Althou the detection of apoptotic cells was evaluated by the TUNEL method, PDGF-BB-stimulated VSMCs did not show apoptotic change in spite of the presence or absence of SB-203580. In addition, the stimulation of PDGF-BB enhanced the levels of arachidonic release and COX-2, and these levels were more increased in VSMCs from diabetic rats. These values were also decreased by SB-203580. These results established that PDGF-BB activated p38 and subsequently regulated cell growth in VSMCs, providing a molecular mechanism by which p38 MAP kinase can cause the development of cardiovascular diseases, including atherosclerosis. Furthermore, this activation was more enhanced in diabetes.
期刊论文(14)
专著(0)
科研奖励(0)
会议论文
五十嵐雅彦: "糖尿病性血管障害の発症機序と予防-血管壁細胞におけるMAP kinaseを中心とした細胞内シグナル伝達機構の変化-"糖尿病合併症. 17・1(印刷中). (2003)
Masahiko Igarashi:“糖尿病血管病的机制和预防 - 以血管壁细胞中 MAP 激酶为中心的细胞内信号转导机制的变化 -”糖尿病并发症 17・1(出版中)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Igarashi M: "Characterization of the Changes of Intracellular Signal Transduction Pathways in the Development of Diabetic Macroangiopathy."Diabetic Complications. 17(1). 36-42 (2003)
Igarashi M:“糖尿病大血管病发展过程中细胞内信号转导途径变化的表征。”糖尿病并发症。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yamaguchi H, Igarashi M, et al.: "Platelet-derived growth factor BB-induced p38 mitogen-activated protein kinase activation causes cell gowth, but not apoptosis, in vascular smooth muscle cells."Endocrine Journal. 48. 433-442 (2001)
Yamaguchi H、Igarashi M 等人:“血小板衍生生长因子 BB 诱导的 p38 丝裂原激活蛋白激酶激活导致血管平滑肌细胞细胞生长,但不会导致细胞凋亡。”内分泌杂志。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Igarashi M, et al.: "Mechanisms of PDGF-induced p38 MAP kinase activation and its pathological significance in vascular wall cells."Proceeding of Kisarazu Conference. 7-11 (2000)
Igarashi M 等人:“PDGF 诱导的 p38 MAP 激酶激活机制及其在血管壁细胞中的病理意义。”木更津会议论文集。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
13
    国内基金
    海外基金
    PDGF-BB介导的PVAT旁分泌调控Sca1+细胞在诱导内皮损伤后内膜 增生中的机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      李凤贺
    • 依托单位:
    PDGF-BB转基因蚕丝胶联合受体基因治疗在DFU中的作用和机制研 究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      范家铭
    • 依托单位:
    微针递送装载VEGF/PDGF-BB基因的腺相关病毒促进烟雾病高龄小鼠颞肌贴敷术后侧支血管生成的研究
    • 批准号:
      82301480
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2023
    • 负责人:
      孙浩耕
    • 依托单位:
    基于PDGF-BB/ERK1/2/巨噬细胞M2极化介导H型血管诱导成骨探究骨碎补总黄酮促进诱导膜技术修复大段骨缺损的机制
    • 批准号:
      82360943
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      33万元
    • 批准年份:
      2023
    • 负责人:
      申震
    • 依托单位: